Cyclin D3 plays a critical role in maturation of precursor T cells and their levels are tightly regulated during this process. Alteration of cyclin D3 levels has been proposed to be important in the development of different human cancers, including malignancies of the lymphoid system. Thus, we have analysed the mechanisms involved in the regulation of cyclin D3 levels. Our results indicate that cyclin D3 is degraded via proteasome and that Thr-283 is essential for its degradation. Wild-type cyclin D3 but not the Thr-283A mutant accumulated ubiquitylated forms after treatment with proteasome inhibitors. We also observed that different type of stresses promote the Thr-283-dependent in vivo degradation of cyclin D3. The analysis of the kinases involved in Thr-283 phosphorylation indicates that all the members of the p38 SAPK family of serine-threonine kinases are able to phosphorylate cyclin D3 at this specific site. Moreover, we found that the overexpression of p38a SAPK2 induce the decrease of cyclin D3 in vivo. These results indicate that p38 SAPK might be involved in the regulation of cyclin D3 levels and suggest that this mechanism is involved in the maturation of precursor T-cells. Alterations of this mechanism might be important for oncogenesis.
Cyclin D3 plays a critical role in maturation of precursor T cells and their levels are tightly regulated during this process. Alteration of cyclin D3 levels has been proposed to be important in the development of different human cancers, including malignancies of the lymphoid system. Thus, we have analysed the mechanisms involved in the regulation of cyclin D3 levels. Our results indicate that cyclin D3 is degraded via proteasome and that Thr-283 is essential for its degradation. Wild-type cyclin D3 but not the Thr-283A mutant accumulated ubiquitylated forms after treatment with proteasome inhibitors. We also observed that different type of stresses promote the Thr-283-dependent in vivo degradation of cyclin D3. The analysis of the kinases involved in Thr-283 phosphorylation indicates that all the members of the p38 SAPK family of serine-threonine kinases are able to phosphorylate cyclin D3 at this specific site. Moreover, we found that the overexpression of p38a SAPK2 induce the decrease of cyclin D3 in vivo. These results indicate that p38 SAPK might be involved in the regulation of cyclin D3 levels and suggest that this mechanism is involved in the maturation of precursor T-cells. Alterations of this mechanism might be important for oncogenesis.
Introduction
Eukaryotic cell division cycle is regulated by the sequential activation and deactivation of different members of a family of serine-threonine kinases named cyclin-dependent kinases (CDKs) (Morgan, 1997) . Cyclin-CDK complexes are specifically formed at different stages of the cell cycle. Cyclin D-CDK4/6 complexes are activated at mid-G 1 , cyclin E-CDK2 are necessary for G 1 /S transition, cyclin A-CDK2 for DNA replication and cyclin B-CDK1 for mitosis entry (Gran˜a and Reddy, 1995) . Progression through G 1 phase is controlled first by CDK4 and CDK6, which bind to Dtype cyclins (cyclin D1, D2 and D3). These three cyclins are encoded by separated genes, showing very high (75-78%) amino-acid identity within the so-called cyclinbox, which mediates CDK binding, whereas the extent of homology outside of this domain is only 39-47% (Inaba et al., 1992; Xiong et al., 1992) . During G1, active cyclin D-CDK4/6 phosphorylates the different members of the pocket proteins family (the retinoblastoma protein (pRB), p107 and p130) leading to the transactivation of genes that allow entry of cells into the S phase (Mayol et al., 1995; Weinberg, 1995; Xiao et al., 1996) .
During development and in adult tissues, the expression pattern of the three D-cyclins is highly orchestrated and often mutually exclusive. Mice lacking each of the D-cyclins genes and more recently mice expressing only cyclin D1, D2 or D3 have been generated (Fantl et al., 1995; Sicinski et al., 1995 Sicinski et al., , 1996 Ciemerych et al., 2002) . Results obtained with single cyclin D-mice indicate that all of them develop normally until late gestation (Ciemerych et al., 2002) . This is because in mutant embryos the tissue-specific pattern of D-cyclins was lost, and these embryos expressed the remaining D-cyclin in all tissues. These findings might be interpreted as an indication that the functions for the three D-type cyclins in driving development, proliferation and differentiation of the majority of cell types are exchangeable. However, in each of the single-cyclin strains it was observed that the remaining cyclin was not able to support the development of a particular, highly selective compartment (Ciemerych et al., 2002) . In the case of cyclin D3 À/À mice, it has been recently found that they fail to undergo normal expansion of immature T lymphocytes and show greatly reduced susceptibility to T-cell malignancies triggered by specific oncogenic pathways (Sicinska et al., 2003) . Thus, cyclin D3 is critically required for the proliferative burst during development of immature T lymphocytes. Cyclin D3 has a potential in cancer since it is overexpressed in different human cancers (Buschges et al., 1999; Ito et al., 2001; Hedberg et al., 2002) and rearrangements of cyclin D3 gene have been observed in malignancies of the lymphoid system such as diffuse large B cell lymphomas or multiple myelomas (Shaughnessy Jr et al., 2001; Filipits et al., 2002) . In light of its vital role in regulating cell cycle in lymphoid cells, it is important to understand the mechanisms behind the regulation of cyclin D3 expression.
Levels of D-cyclins are regulated by the extracellular environment. Quiescent cells contain low levels of this type of cyclin. After mitogenic stimulation the amount of D-cyclins increased and then they associated with CDK4 and CDK6 which become activated (Matsushime et al., 1991) . A number of reports suggest that each Dcyclin is differently regulated. Regulation of Cyclin D1 levels by mitogens has been well established. It is performed by transcriptional and post-transcriptional mechanisms. The low levels of cyclin D1 in quiescent cells are due to the low rate of synthesis and the high activity of GSK3b
, which phosphorylates cyclin D1 at Thr-286 and induces its degradation via proteasome (Diehl et al., 1998) . Mitogenic stimuli induce Rasdependent signaling pathways that increase cyclin D1 transcription and also downregulate GSK3b preventing cyclin D1 phosphorylation and degradation, thus, increasing cyclin D1 levels. It has also been shown that in stress conditions p38 SAPK2 phosphorylates cyclin D1 also at Thr-286, leading to its degradation (Casanovas et al., 2000) .
In contrast, the regulation of cyclin D3 levels is still largely unclear. It is known that the expression pattern of cyclin D3 after mitogenic stimuli is different from that of cyclin D1. For instance, in quiescent liver the levels of cyclin D1 were low, whereas those of cyclin D3 were much higher. After partial hepatectomy (which induced liver cell proliferation) cyclin D1 was substantially upregulated, while cyclin D3 was only modestly induced (Jaumot et al., 1999; Rickheim et al., 2002) . In pancreatic tumor cells mitogenic stimulus produced a fast induction of cyclin D1, whereas that of cyclin D3 was generated much more slowly (Paules and Bachs, unpublished results).
Whereas the factors involved in cyclin D3 transcription are largely unknown, recent reports indicate that cyclin D3 levels might be regulated by degradation via proteasome after hyposmotic stress (Tao et al., 2002) or in cells treated with tumor necrosis factor-a (Hu et al., 2002) . It has also been shown that the formation of ternary complexes cyclin D3-cdk4 and p21
Cip1 or p27
Kip1 stabilizes the D1 and D3 cyclins (Bagui et al., 2003) . We report here that Thr-283 of cyclin D3 is essential for the regulation of its degradation. This residue might be phosphorylated by p38 SAPK , although in contrast to cyclin D1, this residue is not phosphorylated by GSK3b.
Results

Cyclin D3 is rapidly degraded by the proteasome
In order to analyse the mechanisms involved in cyclin D3 degradation, we first measured the cyclin D3 levels in Molt-4 lymphoblastoid cell line after treatment with the protein synthesis inhibitor cycloheximide. Results revealed that cyclin D3 was very rapidly degraded in these cells (Figure 1a ). The treatment of these cells with the proteasomal inhibitors aLLnL, lactacystin or MG132 resulted in a strong time-dependent accumulation of cyclin D3, indicating that cyclin D3 degradation is mediated by the proteasome (Figure 1b ).
Thr-283 is necessary for cyclin D3 ubiquitylation and degradation
The sequence alignment of cyclin D1 and cyclin D3 indicated that Thr-286 of cyclin D1 (the position that is phosphorylated and triggers its degradation) was equivalent to Thr-283 of cyclin D3 (data not shown). To determine whether Thr-283 was implicated in the degradation of cyclin D3, a point mutation was performed to change Thr-283 to alanine. As this mutant protein was tagged with 6-His and Myc it showed slight lower gel mobility and was clearly distinguishable from endogenous cyclin D3 (Figure 2a ). To investigate whether cyclin D3 degradation is regulated by ubiquitin-dependent proteolysis, and whether Thr-283 is involved in this process, COS-1 cells transiently expressing the Thr-283A mutant form of cyclin D3 or wild type (WT) cyclin D3 were treated with the proteasome inhibitor aLLnL for 16 h. Treated cells were lysed and proteins were subjected to SDS-gel electrophoresis and Western blotting with the aim to detect cyclin D3 and/or lower mobility ubiquitylated We also analysed whether the mutation Thr-283A affects cyclin D3 stability. Thus, Molt-4 cells were transfected with cyclin D3-Thr-283A and subsequently treated with cycloheximide. Then, a time course analysis was performed. As shown in Figure 2b , the stability of endogenous cyclin D3 in cycloheximide-treated cells was very low, accordingly to the rapid turnover described above. Interestingly, the mutant cyclin D3-Thr-283A was very stable, showing constant levels for up to 120 min. These results indicate that Thr-283 site is necessary for cyclin D3 degradation.
Different cellular stresses promote cyclin D3 degradation depending on Thr-283
To study the degradation of cyclin D3 in vivo, a Jurkat cell line constitutively overexpressing this cyclin was used. This cell line was stressed with different types of agents namely osmotic stress with NaCl, sodium arsenite and cadmium sulfate. A time course of cyclin D3 protein levels was performed after these stresses by Western blotting. Results indicate a rapid decrease of cyclin D3 in all cases (Figure 3a) .
To determine whether Thr-283 was implicated in stress-triggered degradation of cyclin D3, osmotic stress experiments were performed in MOLT-4 cells, expressing the Thr-283A mutant form of cyclin D3. As shown in Figure 3b , osmotic stress triggered a rapid decrease of endogenous cyclin D3 protein, whereas the levels of the Thr-283A mutant form were unchanged during the Only WT-cyclin D3, but not the mutant expressing cells, shows high mobility forms likely corresponding to polyubiquitylated cyclin D3 when treated with the proteasome inhibitor. Western blot using antiactin antibodies was used as a loading control. (b) Molt-4 cells transfected with 6His-Myc cyclin D3-T283A were treated with cycloheximide to inhibit protein synthesis and cyclin D3 protein levels were analysed in a time course by Western Blot using anticyclin D3 antibodies. In transfected cells, two bands corresponding to the endogenous cyclin D3 (lower Mr) and the 6His-Myc-tagged mutant version (higher Mr) were observed. As it can be seen, the mutated form remained stable during the first 120 min, whereas in contrast the endogenous cyclin D3 decreased These results demonstrate an implication of Thr-283 in the degradation of cyclin D3 by osmotic stress. We also measured the half-life of WTcyclin D3 under normal and stressed conditions. As shown in Figure 3c , in these set of experiments the halflife of cyclin D3 in normal conditions was of 7876 min, whereas under osmotic stress conditions the half-life was reduced to 4377 min.
p38
SAPK2a but not GSK3b phosphorylates cyclin D3 at Thr-283 in vitro All the different treatments mentioned above, used to stress Jurkat cells, induce the activation of p38a
SAPK2a as detected by Western blotting (data not shown). Moreover, a recent report indicates that cyclin D1 might be phosphorylated in Thr-286 by p38a
SAPK2a (Casanovas et al., 2000) . Thus, in vitro kinase assays were performed using recombinant p38a
SAPK2a as a kinase and cyclin D3 as a substrate to analyse whether Thr-283 of cyclin D3 may be phosphorylated by p38a
SAPK2a
. It has also been reported that GSK3b is able to phosphorylate cyclin D1 at Thr-286 and that this phosphorylation targets the cyclin for degradation (Diehl et al., 1998) . Thus, experiments to check whether GSK3b could phosphorylate cyclin D3 were also performed. As shown in Figure 4a , purified GSK3b did not phosphorylate cyclin D3 even it was an active kinase as seen by autophosphorylation and phosphorylation of cyclin D1 as an exogenous substrate. In contrast, p38a SAPK2 did efficiently phosphorylate cyclin D3 (Figure 4b ). In order to identify the phosphorylation site, the mutant cyclin D3-Thr-283A, two fragmented forms of the protein (amino acids 1-224 and 224-292) and the mutated Thr-283A form of the fragment 225-292 were used as exogenous substrates of the kinase reaction. In this case, p38a SAPK2a phosphorylate the WT-full-length protein and the fragment 224-292 containing the intact Thr-283. However, phosphorylation of the proteins containing the mutation Thr-283A was strongly reduced. These results indicate that Thr-283 is the major phosphorylation site of cyclin D3 by p38a SAPK2a .
All members of the SAPK family of kinases might be implicated in the stress-dependent cyclin D3 degradation To further determine whether p38 SAPK2 was implicated in the stress-triggered cyclin D3 degradation, SB203580 (a specific inhibitor for p38a SAPK2a and p38b SAPK2b ) was added to the culture media prior to the osmotic stress treatment. As shown in Figure 5a , the addition of SB203580 to Jurkat-D3 cells partially reverts the stresstriggered decrease in cyclin D3 protein levels at 90 min of hyperosmotic treatment. These results suggest that the partial reversion observed by the addition of SB203580 could be due to the participation in the in vivo phosphorylation of cyclin D3 of the other p38 SAPK isoforms which are not inhibited by SB 203580. To further analyse this possibility, in vitro phosphorylation assays using recombinant active p38b SAPK2b , p38g SAPK3 and p38d SAPK4 were performed. Figure 5b shows that all Figure 4 p38 SAPK2 but not GSK3b phosphorylates cyclin D3. In vitro kinase assays were performed using recombinant purified GSK3b (a) and p38a SAPK2a (b) as kinases and cyclin D1 (D1), cyclin D3 (D3) and the mutant version of cyclin D3 (D3-T283A) as substrates. Also, in the p38a SAPK2a kinase assay, truncated forms of wild-type cyclin D3 (a major N-terminal form (aa 1-224) and a small C-terminal form (aa 225-292)) and a mutant version of the C-terminal form (224-292 T283A) were used. Arrows indicate the position of the different kinases and substrates in the gels. In the experiments with GSK3b, Lithium (Li þ ) was used as a specific inhibitor of this kinase. Coomassie blue stains were used as loading controls SAPK2 and p38d SAPK4 . The coomassie blue stain of one of the gels is showed as a loading control
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Overexpression of p38a
SAPK2a induce the in vivo decrease of cyclin D3
We further analysed the participation of p38 SAPK2 in the degradation of cyclin D3 in vivo. Thus, Cos cells were cotransfected with two vectors harboring p38a
SAPK2a and MKK6 to achieve the expression of an active form of p38a
SAPK2a inside the cells. Then, under these conditions, the levels of endogenous cyclin D3 were studied by Western blotting. As shown in Figure 6 , overexpression of active p38a
SAPK2a induces a clear reduction in the levels of cyclin D3, indicating that p38 SAPK2 is involved in the in vivo degradation of cyclin D3.
Discussion
Recent reports indicate an important role of cyclin D3 in regulating the cell cycle in lymphoid cells and in the genesis of lymphoid malignancies. Thus, understanding of the mechanisms involved in the regulation of cyclin D3 expression is an important goal to be achieved. We report here that Thr283 in cyclin D3 might be phosphorylated by all the members of the p38 SAPK family of serine-threonine kinases and that this phosphorylation targets cyclin D3 for degradation via proteasome.
It is assumed that the cellular levels of all D-type cyclins are regulated by transcriptional and posttranscriptional mechanisms. However, whereas the mechanisms involved in controlling cyclin D1 expression are well understood, not much is known about the mechanisms behind regulation of cyclin D3 expression.
Recently, it has been shown that cyclin D3 might be transcriptionally regulated by the transcription factor E2F1. This assumption is firstly based on a microarray work and more recently by experiments overexpressing E2F1 (Ma et al., 2003) . In these experiments, it was shown that cyclin D3 mRNA is upregulated after E2F1 overexpression also in the presence of the protein synthesis inhibitor cycloheximide, indicating a direct regulation. This was further supported by evidence revealing a high-affinity binding of E2F1 to the cyclin D3 promoter not only in vitro but also in vivo. This transcriptional upregulation by E2F1 is specific for cyclin D3 since in contrast cyclin D1 and cyclin D2 are downregulated by this transcription factor (Watanabe et al., 1998; Ma et al., 2002) .
Recent reports concerning the post-transcriptional regulation of cyclin D3 indicate that it might occur at different levels. On the one hand, it has been shown that the formation of ternary complexes cyclin D3-cdk4 and p21
Cip1 or p27 Kip1 stabilizes the cyclin D3 (Bagui et al., 2003) . On the other hand, it has been reported that cyclic AMP inhibits translation of cyclin D3 in T lymphocytes at the level of elongation by inducing eEF2-phosphorylation and thereby inhibiting its activity (Gutzkow et al., 2003) . Moreover, it is known that cyclin D3 is degraded via proteasome when cells are subjected to tumor necrosis factor (Hu et al., 2002) or under hyposmotic stress (Tao et al., 2002) . Our results indicating that cyclin D3 degradation might be induced in cells under different conditions of hyperosmotic stress (NaCl, sodium arsenite or cadmium sulfate) in a proteasome-depending manner are in agreement with these reports.
Until now, no information was available concerning the site/s of phosphorylation involved in cyclin D3 degradation or the kinase/s responsible for this/ese phosphorylation/s. We report here that Thr-283 is necessary for cyclin D3 degradation via proteasome since mutation of Thr-283 for alanine stabilizes the protein. Interestingly, we found that GSK3b, the kinase involved in the phosphorylation of Thr-286 in cyclin D1 and responsible for deriving it to a proteasomedependent degradation, is not able to phosphorylate cyclin D3. These data clearly indicate that cell cycle regulation of cyclin D3 expression is different to that of cyclin D1 and might explain the different kinetics of cyclin D1 and cyclin D3 expression after mitogenic stimulation.
We report here that the members of the p38 SAPK2 family (p38a
SAPK2a
, p38b
SAPK2b
, p38g SAPK3 and p38d SAPK4 ) are able to phosphorylate cyclin D3 at Thr-283 in vitro. We also found that p38 SAPK2 regulates the degradation of cyclin D3 in vivo. Specifically, we observed that overexpression of p38a SAPK2 clearly reduces the levels of cyclin D3.
Since p38 SAPK2 is activated when cells are placed under stress conditions, it is likely that this family of kinases Figure 6 Overexpression of active p38a SAPK2 induces degradation of the endogenous cyclin D3. Cos-1 cells were transfected with the cDNA for p38a SAPK2 and MKK6DD and after 24 h cells were lysed and subjected to Western blotting using specific anticyclin D3 and antiphospho-P38 antibodies. Results indicate that under these conditions cyclin D3 was degraded. C: control cells; v: empty vectors. Western blot using antiactin antibodies was used as a loading control Degradation of cyclin D3 O Casanovas et al might play an important role in the cell cycle blockade after stress via cyclin D3-downregulation. Cyclin D3 regulation by p38 SAPK2 might be also important for T-cell maturation. It has recently been reported that cyclin D3 is required in lymphocyte development (Sicinska et al., 2003) . Specifically, it has been shown that cyclin D3 À/À mice suffer for an isolated defect in thymocite development characterized by a marked deficit in CD4 þ CD8 þ 'double positive' (DP) T cells. This phenotype stems from a nonredundant role for cyclin D3 in the maturation of CD4 À CD8 À 'double negative' (DN) T cells, the precursors of DP T cells. In the mouse, developing DN T cells successively pass through four stages (DN-1 to DN-4) defined by differential expression of CD44 and CD25 (Sebzda et al., 1999) . Cyclin D3 À/À thymocytes fail to undergo the proliferative burst that normally accompanies the DN-3 to DN-4 transition (Sicinska et al., 2003) . A high level of p38 SAPK2 activity has been observed in DN thymocytes (Sen et al., 1996) . Specifically, the high p38 SAPK2 activity was observed in DN-1 to DN-3 (Diehl et al., 2000) . Then, to progress from DN-3 to DN-4, the p38 SAPK2 activity has to decrease. Interestingly, the levels of cyclin D3 in DN-1 to DN-3 are very low whereas they strongly increase during DN-3 to DN-4 transition (Sicinska et al., 2003) , coinciding with the decrease of p38 SAPK2 activity. Despite the fact that our work has not been performed specifically with these cells, the fact that p38 SAPK2 overexpression induces the degradation of cyclin D3 in vivo strongly suggests that the role of p38 SAPK2 activity during thymocytes maturation might be the regulation of cyclin D3 levels.
Consisting of the growth-promoting functions of cyclin D3, abnormal expression of this cyclin is believed to be a driving force in several human cancers, including B-cell malignancies and multiple myeloma (Florenes et al., 2000; Shaughnessy Jr et al., 2001; Sonoki et al., 2001; Filipits et al., 2002; Pirkmaier et al., 2003) . A recent report indicates that cyclin D3 is also required in mouse and human T-cell malignances (Sicinska et al., 2003) . Moreover, cyclin D3 in collaboration with cdk6 enhances transformation sensitivity in a number of mouse fibroblast cell lines (Chen et al., 2003) . Thus, alterations of the mechanisms involved in the regulation of cyclin D3 levels play an import role in oncogenesis.
Results reported here indicate that p38 SAPK proteins are involved in the regulation of cyclin D3 levels and thus might participate in oncogenesis when their activities are altered. p38 SAPK proteins are typically described as stress-activated kinases that promote inflammation (Kumar et al., 2003) , but these proteins have also been involved in the induction of apoptosis depending on the cell type (Wada and Penninger, 2004) . Moreover, they also participate in the regulation of the cell cycle. It has been proposed that regulation of Cdc25B phosphorylation by p38 SAPK is a critical event for initiating the G2/M checkpoint after ultraviolet radiation (Bulavin et al., 2001) and that p38 SAPK downregulates cyclin D1 (Casanovas et al., 2000) . Thus, alterations of p38 SAPK activity might have a role in oncogenesis by impairing checkpoints, apoptosis or/ and cell proliferation. Although not much information has been reported about the levels and activities of p38 SAPK proteins in tumors, a recent report indicates that the activity of p38 SAPK2 is attenuated in a series of human hepatocarcinoma samples and this decrease in the activity correlates with a higher tumor size, suggesting that it leads to an unrestricted cell growth (Iyoda et al., 2003) . Taking into account these considerations recent reports focus attention on the relevance of p38 SAPK proteins as potential targets in cancer therapy (Morin and Huot, 2004; Olson and Hallahan, 2004) .
Materials and methods
Cell cultures, point mutation and transfection
Molt-4 lymphoblastoid cell line, its stable transfected derivative Molt-4-D3T283A and Jurkat-D3II were grown in RPMI-1640 supplemented with 10% fetal calf serum (FCS). COS cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FCS.
The Cyclin D3 Thr-283 to Ala mutant was obtained by single PCR amplification using a 25-mer initial forward oligonucleotide (5 0 -gggATCCATggAgCTgCTgTgTTgC-3 0 ) and a 51-mer terminal reverse oligonucleotide (5 0 -gAgCTC gAgTCgACTACAggTgTATggCTgTgACATCT gTAggAgCg CTgg-3 0 ) carrying the mutation Thr-283A (underlined). This mutant Cyclin D3 was subcloned into pGEX-KG for bacterial GST-fusion protein expression and pCIneo (Promega) with the addition of 6-Histidine and Myc tags in the N-terminus of the protein for eukaryotic expression.
Stable transfection of Molt-4 cells with pCIneo-6His-MycCyclinD3T283A was performed by electroporation followed by sequential dilution and clone selection with geneticin (GIBCO) in the growing medium. Several independent clones were recovered and analysed for expression of the mutant form of cyclin D3.
COS cells were transiently transfected with pRC/CMVCyclinD3, pCIneo-6His-Myc-CyclinD3T283A, pCMV5-p38 and pEFmlink-MKK6-DD expression vectors using Lipofect (Qiagen) according to the manufacture's instructions. pCMV5-p38 and pEFmlink-MKK6-DD plasmids were a kind gift of Dr Francesc Posas (UPF, Barcelona) and Dr Angel Nebreda (Heidelberg), respectively.
Reagents
Cycloheximide (Sigma) was used at 100 mg/ml final concentration and the proteasome inhibitors at 100 mM for acetylLeucinyl-Leucinyl-nor Leucinal (aLLnL), 10 mM for Lactacystin and 50 mM for MG132 all from Calbiochem. Osmotic stress was performed by the addition of 50 mM NaCl to the culture media and arsenite and cadmium treatments were performed by the addition of 500 mM sodium arsenite (NaAsO 2 ) (Sigma) or 100 mM cadmium sulfate (CdSO 4 ) (Sigma) respectively to the culture media. The p38 SAPK2 inhibitor SB203580 (Calbiochem) was used at 40 mM final concentration.
Western blotting
Western blot analysis was performed using anticyclin D3 (SC-182, Santa Cruz Biotech), and antiphospho-p38 MAP kinase (9211, Cell Signaling) with the corresponding HRP-
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O Casanovas et al conjugated secondary antibody (BioRad). Secondary antibodies were detected with chemiluminiscent reagent ECL (Amersham-Pharmacia) and exposed to ECL films (Amersham-Pharmacia).
Expression and purification of recombinant proteins
All recombinant proteins were obtained as glutathione Stransferase (GST) fusion proteins. Cyclin D3 cDNA was obtained by digesting pET3d-cyclin D3 (Novagen) with NcoIHinDIII and then introduced into the pGEX-KG vector (Guan and Dixon, 1991) at the same sites. Cyclin D3 fragments were obtained by subcloning into pGEX-KG the NcoI-SacI digestion and the SacI-HinDIII digestion from pGEX-cyclin D3 for cyclin D3(1-224) and cyclin D3(225-292) fragments, respectively. For the expression and purification of all these recombinant proteins, the resulting plasmids were transformed into Escherichia coli BL21 (DE3) strain carrying the pLysS plasmid. The expression and purification was performed as described in Neet and Hunter (1995) with minor modifications. After purification, all recombinant proteins were resuspended in a kinase buffer (25 mM HEPES pH 7.4 and 10 mM MgCl 2 ). SAPK2b (Upstate Biotechnology Inc. 14-251; 14-246; 14-249; 14-253), or 40 ng of GSK3b recombinant (Upstate Biotechnology Inc. 14-306), respectively. The reactions were stopped by the addition of 5 Â SDS-PAGE sample buffer and the products were resolved on SDS-PAGE gels. The radioactivity incorporated into the substrates was measured by phosphorimaging (BioRad).
